Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Other hematologic neoplasm 1Lymphoid 1

Conditions

Burkitt Lymphoma 1

Interventions

Cyclophosphamide 95Rituximab 81Specimen Handling 78Magnetic Resonance Spectroscopy 65Biopsy 62Vincristine 50Prednisone 50Doxorubicin 50venetoclax 39obinutuzumab 36fludarabine 35Lenalidomide 30ibrutinib 29Dexamethasone 28Cytarabine 28Methotrexate 27prednylidene 24Etoposide 24deltacortene 23CT-P10 23zanubrutinib 22blinatumomab 22acalabrutinib 22fludarabine phosphate 21Nivolumab 21merphos 19Bendamustine Hydrochloride 17pembrolizumab 16Mercaptopurine 16Calcium Dobesilate 16

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Leyk × Lymphoid × 30 days × Clear all
NCT02101853 2026-06-03

Blinatumomab in Treating Younger Patients With Relapsed B-cell Acute Lymphoblastic Leukemia

National Cancer Institute (NCI)

Phase 3 Active not recruiting
669 enrolled 14 charts
Lymphoid

Burkitt Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡